

# Davide Franceschini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727766/publications.pdf>

Version: 2024-02-01

119  
papers

2,091  
citations

201385

27  
h-index

329751

37  
g-index

121  
all docs

121  
docs citations

121  
times ranked

3206  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	0.8	80
2	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. <i>BMC Cancer</i> , 2017, 17, 829.	1.1	77
3	RapidPlan head and neck model: the objectives and possible clinical benefit. <i>Radiation Oncology</i> , 2017, 12, 73.	1.2	66
4	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. <i>Radiation Oncology</i> , 2016, 11, 76.	1.2	59
5	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210758.	1.1	58
6	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. <i>Breast</i> , 2016, 26, 11-17.	0.9	51
7	Dosimetric trade-offs in breast treatment with VMAT technique. <i>British Journal of Radiology</i> , 2017, 90, 20160701.	1.0	51
8	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 220-226.	0.3	49
9	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2019, 201, 70-76.	0.2	44
10	Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. <i>Cancer</i> , 2012, 118, 3236-3243.	2.0	39
11	RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategies. <i>Radiation Oncology</i> , 2019, 14, 187.	1.2	39
12	Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. <i>Radiation Oncology</i> , 2016, 11, 120.	1.2	38
13	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
14	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 507-515.	0.4	36
15	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 805-818.	1.0	36
16	Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 1197-1203.	1.2	35
17	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	1.2	35
18	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. <i>Cancer Research and Treatment</i> , 2017, 49, 20-28.	1.3	34

#	ARTICLE	IF	CITATIONS
19	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. <i>Clinical Oncology</i> , 2016, 28, e173-e178.	0.6	33
20	Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. <i>Radiologia Medica</i> , 2019, 124, 662-670.	4.7	33
21	Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 521-528.	1.2	32
22	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. <i>Radiation Oncology</i> , 2020, 15, 92.	1.2	31
23	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. <i>Cancer Treatment Reviews</i> , 2016, 50, 1-8.	3.4	30
24	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.4	30
25	Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 613-618.	0.5	29
26	Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 785-793.	0.4	29
27	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	1.3	29
28	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	1.0	29
29	CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. <i>World Journal of Urology</i> , 2016, 34, 311-317.	1.2	28
30	Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. <i>Journal of Chemotherapy</i> , 2012, 24, 279-284.	0.7	27
31	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102894.	2.0	27
32	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1293-1299.	1.2	26
33	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. <i>Radiation Oncology</i> , 2017, 12, 200.	1.2	26
34	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880388.	0.8	26
35	Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. <i>Medical Oncology</i> , 2019, 36, 48.	1.2	25
36	Organs at risk in lung SBRT. <i>Physica Medica</i> , 2017, 44, 131-138.	0.4	24

#	ARTICLE	IF	CITATIONS
37	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	1.1	24
38	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. Radiation Oncology, 2015, 10, 224.	1.2	22
39	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 614-621.	0.4	22
40	The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study. Clinical Oncology, 2020, 32, 26-34.	0.6	22
41	Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. Cancers, 2021, 13, 3590.	1.7	21
42	Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 Patients treated with a prospective margin-directed policy. Radiotherapy and Oncology, 2013, 108, 273-278.	0.3	20
43	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiotherapy and Oncology, 2018, 127, 326-331.	0.3	17
44	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with â€œcurativeâ€ intent. Lung Cancer, 2020, 141, 1-8.	0.9	17
45	Simultaneous integrated boostâ€”intensityâ€modulated radiotherapy in head and neck cancer. Laryngoscope, 2013, 123, E97-103.	1.1	16
46	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	0.6	16
47	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.4	15
48	Preliminary Results of a Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). Clinical Breast Cancer, 2021, 21, 231-238.	1.1	15
49	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 163-169.	0.3	14
50	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14
51	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast, 2018, 42, 31-37.	0.9	14
52	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	1.2	14
53	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkinâ€™s lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	1.2	14
54	Adjuvant Radiotherapy for a Prostate Cancer After Renal Transplantation and Review of the Literature. Japanese Journal of Clinical Oncology, 2011, 41, 1282-1286.	0.6	13

#	ARTICLE	IF	CITATIONS
55	Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature. Pediatric Neurosurgery, 2012, 48, 35-41.	0.4	13
56	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. British Journal of Radiology, 2017, 90, 20170422.	1.0	13
57	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. World Neurosurgery, 2017, 105, 184-190.	0.7	13
58	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	0.8	13
59	A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer.. Strahlentherapie Und Onkologie, 2020, 196, 922-931.	1.0	12
60	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2289-2297.	1.2	12
61	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. Radiotherapy and Oncology, 2020, 150, 184-190.	0.3	12
62	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. Radiologia Medica, 2019, 124, 315-322.	4.7	11
63	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. Laryngoscope, 2020, 130, E163-E170.	1.1	11
64	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. British Journal of Radiology, 2020, 93, 20190627.	1.0	11
65	Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis. Clinical Breast Cancer, 2020, 20, 527-533.	1.1	11
66	Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen. Clinical Breast Cancer, 2013, 13, 247-253.	1.1	10
67	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncology, 2019, 15, 3775-3782.	1.1	10
68	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219.	4.7	10
69	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, 480-486.	1.1	10
70	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 885.	1.7	10
71	Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy. Radiologia Medica, 2019, 124, 854-859.	4.7	9
72	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. Clinical and Experimental Metastasis, 2020, 37, 565-573.	1.7	9

#	ARTICLE	IF	CITATIONS
73	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 927-936.	1.2	9
74	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 951-956.	0.5	8
75	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. <i>British Journal of Radiology</i> , 2019, 92, 20190252.	1.0	8
76	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO) Lung Working Group. <i>Radiologia Medica</i> , 2019, 124, 136-144.	4.7	8
77	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 608-616.	1.0	8
78	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	1.0	8
79	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e767-e773.	1.1	8
80	Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer. <i>Cancer Investigation</i> , 2015, 33, 188-192.	0.6	7
81	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. <i>Radiologia Medica</i> , 2016, 121, 229-237.	4.7	7
82	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 385-391.	1.0	7
83	Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2267-2276.	1.2	7
84	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. <i>European Journal of Cancer</i> , 2021, 143, 75-77.	1.3	7
85	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 152, 1-6.	0.9	7
86	Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center. <i>Clinical Breast Cancer</i> , 2021, 21, 329-336.	1.1	7
87	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. <i>British Journal of Radiology</i> , 2019, 92, 20190021.	1.0	6
88	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 133-140.	1.0	6
89	Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. <i>Anticancer Research</i> , 2017, 37, 7057-7062.	0.5	6
90	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. <i>British Journal of Radiology</i> , 2017, 90, 20170022.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Breast Cancer Treated with Surgery Followed by Radiotherapy. <i>World Neurosurgery</i> , 2018, 110, e281-e286.	0.7	5
92	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019, 14, e0224027.	1.1	5
93	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1227-1234.	1.2	5
94	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	1.2	5
95	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 710-718.	1.0	5
96	Hypofractionated volumetric modulated arc therapy in ductal carcinoma <i>in situ</i> : toxicity and cosmetic outcome from a prospective series. <i>British Journal of Radiology</i> , 2018, 91, 20170634.	1.0	4
97	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. <i>British Journal of Radiology</i> , 2019, 92, 20181026.	1.0	4
98	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. <i>Clinical Lung Cancer</i> , 2020, 21, 86-93.	1.1	4
99	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	1.2	4
100	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. <i>Practical Radiation Oncology</i> , 2021, 11, e329-e338.	1.1	4
101	Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single institution experience. <i>Radiologia Medica</i> , 2013, 118, 570-582.	4.7	3
102	Radiation therapy in small cell lung cancer: a national Italian survey. <i>Radiologia Medica</i> , 2018, 123, 554-560.	4.7	3
103	Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2069-2077.	1.2	3
104	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 101-110.	0.3	3
105	Treatment of invasive male breast cancer: a 40-year single-institution experience. <i>Radiologia Medica</i> , 2013, 118, 476-486.	4.7	2
106	A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy". <i>Lung Cancer</i> , 2021, 157, 165-166.	0.9	2
107	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2022, 61, 553-559.	0.8	2
108	Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report. <i>Tumori</i> , 2013, 99, e233-6.	0.6	2



#	ARTICLE	IF	CITATIONS
109	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. Expert Review of Anticancer Therapy, 2020, 20, 743-753.	1.1	1
110	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the "radio talk"™ webinars. Expert Review of Anticancer Therapy, 2022, 22, 549-559.	1.1	1
111	Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer Investigation, 2014, 32, 445-450.	0.6	0
112	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. Cancer Management and Research, 2021, Volume 13, 7009-7031.	0.9	0
113	Title is missing!. , 2019, 14, e0224027.		0
114	Title is missing!. , 2019, 14, e0224027.		0
115	Title is missing!. , 2019, 14, e0224027.		0
116	Title is missing!. , 2019, 14, e0224027.		0
117	Title is missing!. , 2019, 14, e0224027.		0
118	Title is missing!. , 2019, 14, e0224027.		0
119	Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy. Current Oncology, 2022, 29, 4893-4901.	0.9	0